Abstract
Alterations of gene expression by miRNAs contribute substantially to genetic regulation and cellular functions.
We conducted a comprehensive study in 53 individuals before and after the administration of the 2010-2011 seasonal inactivated influenza vaccine to characterize lymphocyte-specific miRNA expression (in purified B cells, CD4+ T cells, CD8+ T cells and NK cells) and its effect on influenza vaccine-induced immune outcomes (hemagglutination inhibition antibody titers/HAI, viral neutralizing antibody titers /VNA and memory B cell ELISPOT).
Overall, we observed relatively stable miRNA expression before/after influenza vaccination. Our statistical analysis uncovered three baseline miRNAs (miR-150-3p, miR-629-5p and miR-4443) that were significantly correlated with influenza vaccine-induced immune outcomes in different cell types. Predictive modeling of influenza vaccine-induced HAI/VNA titers identified a set of specific baseline miRNAs in CD4+ T cells as factors predictive of antibody responses. A pathway enrichment analysis on the putative target genes revealed several regulated signaling pathways and functions: TGF-β signaling, PI3K-Akt signaling, p53 signaling, MAPK signaling, TNF signaling and C-type lectin receptor signaling, as well as cell adhesion and adherens junctions, and antiviral host response.
In conclusion, our study offers evidence for the role of epigenetic modification (miRNAs) on influenza vaccine-induced immunity. After validation, identified miRNAs may serve as potential biomarkers of immune response after influenza vaccination.
Highlights
Host miRNA expression is relatively stable before and after influenza vaccination
miR-150-3p, miR-629-5p and miR-4443 were correlated with immunity across cell types
Specific CD4+ T cell miRNAs are predictive of antibody responses
Identified miRNAs may serve as biomarkers of immune response after influenza vaccine
Competing Interest Statement
Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland provides consultative advice to AiZtech; AstraZeneca; Emergent; GlaxoSmithKline; Invivyd; Johnson & Johnson/Janssen; Medicago; Medscape/WebMD; Merck & Co. Inc.; Moderna; NovaSource/NorthStar Energy; Novavax; Ocugen; Regeneron; Sanofi; Syneos Health; and Valneva. Dr. Poland is an adviser to the White House and World Health Organization on COVID-19 vaccines and monkeypox, respectively. Drs. Poland and Ovsyannikova hold patents related to vaccinia and measles peptide vaccines. Drs. Kennedy, Poland, and Ovsyannikova hold a patent related to vaccinia peptide vaccines. Drs. Poland, Kennedy, Ovsyannikova, and Haralambieva hold a patent related to the impact of single nucleotide polymorphisms on measles vaccine immunity. Drs. Poland, Kennedy, and Ovsyannikova have received grant funding from ICW Ventures for preclinical studies on a peptide-based COVID-19 vaccine. Dr. Kennedy has received funding from Merck Research Laboratories to study waning immunity to mumps vaccine. Dr. Kennedy also offers consultative advice on vaccine development to Merck & Co. and Sanofi Pasteur. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies.
Funding Statement
The study was funded by the National Institute of Allergic and Infectious Diseases of the National Institutes of Health (U01 AI 089859/Bioinformatics Approach to Influenza A/H1N1 Vaccine Immune Profiling and R01AI132348), the Human Immunology Project Consortium Infrastructure and Opportunities Fund, and a grant from the Mayo Clinic Biomarker Discovery program (grant C4330915).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Mayo Clinic Institutional Review Board approved all study procedures and written informed consent was obtained from each participant.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
All data is available at ImmPort.org (SDY67).
